


# PRODUCT INFORMATION



## NU 2058

Item No. 21415

**CAS Registry No.:** 161058-83-9  
**Formal Name:** 6-(cyclohexylmethoxy)-9H-purin-2-amine  
**Synonym:** O<sup>6</sup>-(Cyclohexylmethyl)guanine  
**MF:** C<sub>12</sub>H<sub>17</sub>N<sub>5</sub>O  
**FW:** 247.3  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 241, 282 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

NU 2058 is supplied as a crystalline solid. A stock solution may be made by dissolving the NU 2058 in the solvent of choice, which should be purged with an inert gas. NU 2058 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of NU 2058 in ethanol is approximately 1 mg/ml and approximately 25 mg/ml in DMSO and DMF.

NU 2058 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, NU 2058 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. NU 2058 has a solubility of approximately 0.12 mg/ml in a 1:7 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

NU 2058 is an inhibitor of cyclin-dependent kinase 1 (Cdk1) and Cdk2 (IC<sub>50</sub>s = 7.0 and 17 μM, respectively).<sup>1,2</sup> Increased Cdk activity is often associated with human tumors, and inhibitors of Cdk, including NU 2058, can arrest cell cycling in cancer cells *in vitro*.<sup>2-4</sup>

### References

1. Hardcastle, I.R., Arris, C.E., Bentley, J., *et al.* N<sup>2</sup>-substituted O<sup>6</sup>-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2. *J. Med. Chem.* **47**, 3710-3722 (2004).
2. Sayle, K.L., Bentley, J., Boyle, F.T., *et al.* Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. *Bioorg. Med. Chem. Lett.* **13(18)**, 3079-3082 (2003).
3. Johnson, N., Bentley, J., Wang, L.-Z., *et al.* Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. *Br. J. Cancer* **102(2)**, 342-350 (2010).
4. Rigas, A.C., Robson, C.N., and Curtin, N.J. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. *Oncogene* **26(55)**, 7611-7619 (2007).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/18/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM